Crexont capsules — Cigna
Parkinson’s disease
Preferred products
- carbidopa-levodopa immediate-release tablets (generic)
- carbidopa-levodopa extended-release tablets (generic only)
Initial criteria
- If the patient has tried one Step 1 Product, approve a Step 2 Product. Note: A trial of Sinemet also satisfies the requirement.
- OR If the patient is currently taking Crexont capsules or Rytary capsules, approve.
Approval duration
1 year